Theravance Biopharma, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
CA
Business Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, CA, KY1-1104
Mailing Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, CA, KY1-1104
Phone
650-808-6000
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$105.89M
Net Income
$485.57M
Total Assets
$167.81M
Cash & Equivalents
$2.10
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 25, 2026 | View on SEC |
| 10-K Annual financial report | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
Annual Reports
10-K
March 23, 2026
- Total revenue increased by 11.3% in 2025, reaching $95.2 million, driven by an 8.9% growth in Yupelri partnership revenue.
- The company significantly reduced its net loss by 32.2% in 2025, demonstrating improved operational efficiency through lower R&D and SG&A costs.
Material Events
8-K
Other
March 19, 2026
High Impact
- Theravance Biopharma will now focus on other pipeline drugs, including TD-9855 (Phase 2 for chronic cough) and TD-0903 (early lab for IBD), and partnered respiratory programs.
- The company reported approximately $350 million in cash and investments as of December 31, 2025, providing financial resources for continued operations.
8-K
Strategy Change
March 3, 2026
High Impact
- Targeted 60% reduction in annual operating expenses, equating to $70 million in annual savings.
- Shift to a leaner, commercially focused entity, prioritizing existing assets (YUPELRI®) and royalty streams.
Insider Trading
STRONG SELL
1 insiders
6 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.